Although YY1 and Shh did not show survival prediction potential, overexpression of ZNF322A correlated with poor OS (P=0.001; Figure 5B) and PFS (P=0.039; Figure 5C) in lung cancer patients. This evidence concerns the gene ZNF322 and lung cancer.